STADA Arzneimittel AG (STDAF.PK) Thursday reported an increase in preliminary earnings for the full-year and said, on the basis of the improved results, it is expected to increase the dividend payment for 2012. Further, the firm adopted a positive outlook for 2013 and confirmed the long-term view for 2014.
According to preliminary 2012 figures, the firm said sales for the full year are expected to rise by 7 percent to 1.837 billion euros. It also expects EBITDA to increase by 45 percent to 323.8 million euros. Also, reported earnings per share are expected to increase to 1.46 euros, up from the prior-year figure of 0.37 euros. Adjusted for one-time special effects and non-operational effects from the measurement of derivative financial instruments, earnings per share are expected to be 2.50 euros compared with 2.49 euros for the year-ago period.
The company is expected to roll out a full-year dividend of 0.50 euros per share, a 35.1 percent increase over the prior full-year dividend of 0.37 euros per share.
STADA Arzneimittel also said it expects further growth of sales and earnings for 2013 and 2014. The company backed the long-term view for 2014, that is sales of approximately 2.15 billion euros, at an adjusted level, EBITDA of approximately 430 million euros and net income of approximately 215 million euros at minimum.
For comments and feedback contact: editorial@rttnews.com
Business News
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.